|Day's Range||3.9400 - 4.3500|
Piper Jaffray initiates CV Sciences with an overweight rating and a price target that reflects an upside of more than 60%. CV Sciences CEO Joe Dowling joins Yahoo Finance's Zack Guzman and Sibile Marcellus, along with Carleton English, New York Post Hedge Fund Reporter, to discuss.
WOONSOCKET, R.I., Aug. 19, 2019 /PRNewswire/ -- CVS Health Corporation ("CVS Health", NYSE: CVS) announced today the final results of the previously announced cash tender offers (the "Any and All Tender Offers" and each an "Any and All Tender Offer") for (1) any and all of its 3.125% Senior Notes due 2020 (the "2020 Any and All Notes") and (2) any and all of its 4.125% Senior Notes due 2021, the 4.125% Senior Notes due 2021 issued by its wholly-owned subsidiary, Aetna Inc. ("Aetna") and the 5.450% Senior Notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna (collectively, the "2021 Any and All Notes" and together with the 2020 Any and All Notes, the "Any and All Notes"). The Any and All Tender Offers expired at 5:00 p.m., New York City time, on August 14, 2019 (the "Any and All Expiration Date").
NEW YORK, NY / ACCESSWIRE / August 18, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 14, 2019 to file lead plaintiff applications in a securities class action lawsuit against CVS Health Corporation , if they formerly held shares of Aetna Inc.
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
Robbins Geller Rudman & Dowd LLP (http://www.rgrdlaw.com/cases/cvshealth/) today announced that a class action has been commenced by an institutional investor on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS’s acquisition of Aetna on November 28, 2018. The Private Securities Litigation Reform Act of 1995 permits any former Aetna shareholders who acquired CVS shares in exchange for their Aetna shares in connection with CVS’s acquisition of Aetna to seek appointment as lead plaintiff.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Aetna Inc. New York, August 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Aetna Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
PLANTATION, Fla. , Aug. 15, 2019 /PRNewswire/ -- Aetna Better Health of Florida , a CVS Health company (NYSE: CVS), has been awarded a new, statewide contract by the Florida Healthy Kids Corporation, a ...
WOONSOCKET, R.I., Aug. 15, 2019 /PRNewswire/ -- CVS Health Corporation ("CVS Health", NYSE: CVS) announced today the results of the previously announced cash tender offers (the "Any and All Tender Offers" and each an "Any and All Tender Offer") for (1) any and all of its 3.125% Senior Notes due 2020 (the "2020 Any and All Notes") and (2) any and all of its 4.125% Senior Notes due 2021, the 4.125% Senior Notes due 2021 issued by its wholly-owned subsidiary, Aetna Inc. ("Aetna") and the 5.450% Senior Notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna (collectively, the "2021 Any and All Notes" and together with the 2020 Any and All Notes, the "Any and All Notes").
Among marijuana stocks, very few have achieved profitability. But sooner or later, every company needs to reach that milestone.That sounds obvious, like "Business 101." In fact, it's one of the most basic requirements for a stock to trade on the "Big Board," the New York Stock Exchange (NYSE)… and also for the Nasdaq, for that matter.And yet, in the cannabis industry, Charlotte's Web (OTCMKTS:CWBHF) is one of the few that can deliver positive earnings! That's just one reason I want to put it on your radar today.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCharlotte's Web was one of the original hemp-cannabidiol (CBD) companies, and perhaps the biggest success story of Colorado's legal cannabis boom. * 10 Stocks Under $5 to Buy for Fall CWBHF is also my pick for InvestorPlace's Best Stocks for 2019 contest - but really, it's among the top marijuana stocks for the next three years, at least, and here's why:With news Wednesday that the company's Q2 revenue rang in at $25 million, Charlotte's Web is expecting to post sales of $120-$170 million for the year. (At the midpoint, that puts the stock at a very attractive price-to-sales ratio of just 6X). But next year, analysts are expecting sales of $348 million… and $444 million the year after that.If that sounds lofty, keep in mind that Charlotte's Web CBD will soon be in twice as many stores as it was last year. From a niche product that was mainly found in health stores, you can now buy it at "big box" stores like CVS Health (NYSE:CVS) and, now, Kroger (NYSE:KR).The deal with Kroger, announced on July 31, is big; it adds 1,350 stores (in 22 states) to Charlotte's Web's retail network. The total number of retail locations carrying the company's products stood at 7,817 at the end of the quarter, up 1,926.Demand for hemp-CBD and this particular brand is booming, and to keep up, Charlotte's Web just expanded into the prestigious Colorado Technology Center, strategically located between the cities of Boulder and Denver.With the new location, Charlotte's Web will quadruple its footprint. After all, to make hemp-CBD, you've got to process a lot of hemp. And while operations will begin "early next year," the growth opportunity there will be just beginning.The Colorado Tech Center is better known for its tech startups, and Charlotte's Web is bringing some of that same energy to this expansion. Rather than resorting to CBD extraction techniques that are "decades old," their ambition is to use state-of-the-art technology to maintain what's always been the company's edge: "the highest-quality products."Here's another significant edge: reputation. The truth about the CBD market is that there are a lot of bad players - and those other guys will soon be removed by the coming wave of federal regulation. As I always say in Investment Opportunities, marijuana stocks are one group that needs regulators. And as a legitimate leader of the industry, Charlotte's Web will be the beneficiary.That's the context of the company's eye-catching earnings-per-share (EPS) projections. Already leading the pack with $0.27 per share expected this year, that should increase to $0.74 next year and $1.06 in 2021.The stock is up 65% since I picked it for the Best Stocks contest, even after it stumbled on Wednesday's quarterly report. But given these projections, CWBHF is still a steal as it trades around $20 on the over-the-counter (OTC) markets.As for the major stock exchanges - which open up a whole new world to companies like this - Charlotte's Web is on the right track to meet the NYSE and Nasdaq's earnings requirements for the long term. And I always believe in investing in a great stock early - BEFORE it makes that jump. Marijuana Stocks: Another "Jumper" Stock You Won't Want to MissGiven that it's fully legalized on its federal level, Canada is always a popular place to look for marijuana stocks, too. And one of my picks there just announced that it will "jump" to the Toronto Stock Exchange. (Charlotte's Web did, too, for that matter.)When a company moves to the big leagues, it opens up lots of doors for financing, offerings, and big institutional money. It's like the market's "seal of approval": an elite status with long-term benefits to the share price.In the next six to 12 months, I expect this particular Canadian stock to announce a second uplisting - to a U.S. exchange. That would be even more significant.Business wise, I'd put its extraction operation up against anyone's. At Investment Opportunities, you can get all the details on this and other up-and-coming cannabis stocks in the legalization mega-trend. Timing is EverythingEarly stage investing can be exciting… but also tricky.When a new industry booms - when billions of dollars are up for grabs - you can be sure all kinds of people will rush into the sector and try to get their share.Some of the companies will have smart, hardworking people running the show… great people to invest with. But, let me tell you, some of these folks aren't the kind of people you'd ever want to invite over for dinner… let alone do business with.That's a fact of life in any industry. But this challenge is magnified in a new industry with massive potential - like the legal marijuana industry.This is why it is critical to have a system… a framework for evaluating legal marijuana stocks.A path to profitability is certainly one of the things I look for here. But there's a little more to it than that!So, I created a 5-Factor Analytical Model for evaluating newly public legal marijuana companies to as part of my Cannabis Cash Calendar.I've put my model to the test in recent weeks to uncover my next Cannabis Cash Calendar recommendation… which I just released on Tuesday to my Investment Opportunities readers. But there is still time for you to get in on it, too, as it's still under my buy price!The opportunity in legal weed is much like the opportunity internet stocks offered in 1994… or that bitcoin offered in 2015. It is set to grow so much over the next 10 years that it will turn out to be one of the three biggest investment opportunities of your entire life - no matter when you were born.Click here to learn more and find out how you can get immediate access to my new recommendation.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks Under $5 to Buy for Fall * 5 Stocks to Avoid Amid the Ongoing Trade War * 7 5G Stocks to Buy Now for the Future The post Marijuana Stocks: Catch the Next Hot Pot Stock Before It 'Jumps' appeared first on InvestorPlace.
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition is gaining a strong momentum.
Zacks.com featured highlights include: Diebold Nixdorf, CVS Health, AmerisourceBergen, AutoNation and Clearwater Paper
Walgreens and CVS Health shares are trading at a low valuation multiple. The stocks have fallen 22.3% and 8.7%, respectively, in 2019.
Investors aim to generate maximum returns from their portfolio. Therefore, it is in their best interests to pay heed to well-researched information accumulated by brokers.
Despite rapidly changing dynamics in the pharmaceutical industry, CVS Health looks like the clear leader.
CVS Health (NYSE:CVS) stock is getting results combining the health insurance income of Aetna with the outgo of its pharmacies and health services.Source: Shutterstock The proof came in its second-quarter earnings report, with adjusted net income of $4 billion, $1.89 earnings per share and adjusted revenue of $63.4 billion. Same store sales were up 4.2%, pharmacy market share was up 1.2% at 26.6% and the company generated $5.3 billion in operating cash flow.The results put CVS stock in another league. Stop comparing it to Walgreens Boots Alliance (NASDAQ:WBA), which saw falling earnings on $34.6 billion of revenue. Instead, compare it to UnitedHealth Group (NYSE:UNH), which earned $3.3 billion, $3.60 per share fully adjusted, on revenue of $60.6 billion in its most recent quarter.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Dividend Aristocrat Stocks to Buy Now No Matter What The CVS stock results "demolished" Wall Street expectations but should not have been a surprise. CVS vs. UnitedHealthIt has been a long time since any health insurer could go toe-to-toe with UnitedHealth. The company has spent 15 years installing technology through its Optum unit, integrating the former Catamaran pharmacy benefit manager. It is by far the largest player in the health insurance industry, with almost 13% of all premiums.UnitedHealth's size, and the cost control it generates, have also benefited investors. The shares are up over 200% over the last five years, while CVS has fallen in value by 25%. But Aetna, one of the companies that had fallen behind, merged with CVS pharmacies -- and therefore with Caremark, CVS' pharmacy benefits manager -- gaining low-cost facilities to create a second large player.CVS Health is now going to start capitalizing on that synergy by expanding its home dialysis service, creating an Amazon-like membership service called CarePass and continuing to open stores while Walgreens cuts back.I have been pounding the table for the potential of this merger for some time. That's because combining pharmacy facilities with insurance is the best way for the private market to generate cost control. My model here has been Centene (NYSE:CNC), whose combination of premium income and facilities lets it turn a profit even on Medicare and Medicaid contracts. What Business WantsPoliticians debate whether a public plan or one with private options can bring cost control. The market is saying whoever holds the money must be able to control how it is spent.That's what UnitedHealth and Centene have, and what CVS Health is gaining. About 75% of a health plan's cost relates to chronic conditions, preventable things like heart disease, kidney failure and diabetes. Having control of the facilities, making sure people take their medicine and keeping people out of the hospital is the key to reducing costs.All players in the healthcare game know this. That's why drug companies are desperate to keep even Medicare from bargaining for lower prices. That's why hospitals fear the CVS-Aetna merger. The "front door" to care in the past has always been a doctor or hospital. CVS is making it your local pharmacy. The Bottom Line on CVS StockUnitedHealth has three times the market cap of CVS, even though CVS now brings in more revenue.CVS' integration with Aetna is still in its early stages, and it's already showing it can deliver fatter margins than UnitedHealth.All healthcare stocks will remain under pressure as the political debate continues. CVS Health already has a 50-cent-per-share dividend yielding 3.4%. Its dividend yield is better than UnitedHealth's $1.08 per share dividend, yielding 1.76%.The result of the political debate is going to be a managed care model, combining income with outgo. That's where CVS Health is going.Dana Blankenhorn is a financial and technology journalist. He is the author of the environmental story, Bridget O'Flynn and the Bear, available at the Amazon Kindle store. Write him at firstname.lastname@example.org or follow him on Twitter at @danablankenhorn. As of this writing he owned shares in CVS. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Dividend Aristocrat Stocks to Buy Now No Matter What * 7 Stocks to Buy to Ride the Vegan Wave * 4 Safe Stocks to Buy Amid Trade War Turbulence The post Start Comparing CVS Stock to UnitedHealth appeared first on InvestorPlace.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.